Johnson & Johnson forecasts 2026 sales up to $101.4B, EPS $11.11

Johnson & Johnson guided 2026 sales of $100.8 billion to $101.4 billion, with adjusted EPS of $10.96 to $11.11.

The midpoint of the sales range, $101.1 billion, would represent roughly 3% growth from the trailing twelve-month revenue of $98 billion through the second quarter. JNJ reported net income of about $5.6 billion in the June quarter, a margin of roughly 22%, according to its latest filing.

The guidance puts JNJ as a steady income generator for investors, with a dividend yield of about 2%. However, Eli Lilly has been closing the revenue gap, driven by its obesity drugs Mounjaro and Zepbound, which generated combined sales of more than $15 billion in the first quarter alone.

JNJ's pharmaceutical portfolio spans immunology, oncology, and neuroscience, while its medical technology segment provides diversification beyond drug revenue. The company recently entered an agreement to acquire Firefly Bio, adding to its pipeline.

JNJ's quarterly revenue has shown steady growth over the past two years, rising from $22.5 billion in the third quarter of 2024 to $25.3 billion in the second quarter of 2026. The company's net income margin of about 22% reflects the pricing power and patent protections typical of large pharmaceutical companies.

Eli Lilly, by contrast, has grown faster, with revenue climbing from $11.4 billion in the third quarter of 2024 to $19.8 billion in the first quarter of 2026 — a 74% increase over that period. Lilly's net income margin of roughly 37% shows the profitability of its metabolic drug franchise.

Both companies compete in immunology and oncology, but Lilly's lead in the obesity market has given it a growth trajectory that JNJ, with its more diversified and slower-growing business, cannot match. JNJ's advantage lies in its stability and diversification across pharmaceuticals and medical devices, which provides a buffer against patent cliffs in any single drug category.

The broader pharma sector has seen a shift in investor focus toward high-growth metabolic and oncology therapies, with companies like Lilly and Novo Nordisk commanding premium valuations. JNJ's guidance reflects a more conservative growth profile that appeals to income-oriented investors seeking reliable dividends and steady returns.

The guidance range of $100.8 billion to $101.4 billion implies management expects continued demand across both the pharma and medtech segments. The adjusted EPS forecast of $10.96 to $11.11 suggests the company expects to maintain margins despite competitive pressure from Lilly and other rivals.

Investors will watch upcoming quarterly results for signs of whether Eli Lilly's momentum is affecting JNJ's market share in key therapeutic areas such as immunology and oncology. JNJ's next earnings report will provide the first look at whether the company is on track to hit its 2026 targets.

This article is for informational purposes only and does not constitute investment advice.